Pingli Zhu, Zhuoshi Wang, Liang-bao An, Ling-Xian Xu
{"title":"Intravitreal conbercept injection for recurrent vitreous haemorrhage after diabetic vitrectomy","authors":"Pingli Zhu, Zhuoshi Wang, Liang-bao An, Ling-Xian Xu","doi":"10.3760/CMA.J.ISSN.1006-4443.2017.08.006","DOIUrl":null,"url":null,"abstract":"Objective \nTo assess the effects of intravitreal conbercept in treating delayed post-vitrectomy (4 weeks after surgery) diabetic vitreous hemorrhage (PVDVH). \n \n \nMethods \nOf 36 consecu-tive patients (36 eyes) with delayed PVDVH were assigned to tow groups, the study group (17 eyes) and the control group (19 eyes). The study group was treated with intravitreal conbercept, and repeated injection was given after 4 weeks in cases with no obvious blood absorption, until the blood was absorbed completely. The control group was given Chinese traditional medicine and iodized lecithin. The average follow-up duration was 8.5±2.5 months (ranged, 5~13 months). \n \n \nResults \nVCT of the study group was 2-8 weeks, mean 5.3±2.3 weeks, with average injection 2.2±0.8 times. Four eyes had developed recurrent vitreous hemorrhage (VH), but all of the eyes had a clear vitreous at the end of study period, and no vitrectomy surgery was needed. In the control group, eight eyes had spontaneous reabsorption in 3-9 weeks, mean 6.7±2.5 weeks, 11 eyes developed recurrent VH, the blood of one eye finally had been absorbed, 10 eyes had persistent VH, 4 eyes of them had iris neouvasculrization, and 4 eyes of them had retinal detachment, and finally these 10 eyes underwent revitrectomy surgeries. The vision of the study group was better than that in the control group. \n \n \nConclusions \nIntravitreal conbercept treatment can accelerate the clear-up of the VH, reduce the complication and the need of revitrectomy for PVDVH. \n \n \nKey words: \nConbercept; Diabetic retinopathy; Recurrent vitreous haemorrhage","PeriodicalId":10236,"journal":{"name":"中国实用眼科杂志","volume":"57 1","pages":"771-774"},"PeriodicalIF":0.0000,"publicationDate":"2017-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实用眼科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1006-4443.2017.08.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To assess the effects of intravitreal conbercept in treating delayed post-vitrectomy (4 weeks after surgery) diabetic vitreous hemorrhage (PVDVH).
Methods
Of 36 consecu-tive patients (36 eyes) with delayed PVDVH were assigned to tow groups, the study group (17 eyes) and the control group (19 eyes). The study group was treated with intravitreal conbercept, and repeated injection was given after 4 weeks in cases with no obvious blood absorption, until the blood was absorbed completely. The control group was given Chinese traditional medicine and iodized lecithin. The average follow-up duration was 8.5±2.5 months (ranged, 5~13 months).
Results
VCT of the study group was 2-8 weeks, mean 5.3±2.3 weeks, with average injection 2.2±0.8 times. Four eyes had developed recurrent vitreous hemorrhage (VH), but all of the eyes had a clear vitreous at the end of study period, and no vitrectomy surgery was needed. In the control group, eight eyes had spontaneous reabsorption in 3-9 weeks, mean 6.7±2.5 weeks, 11 eyes developed recurrent VH, the blood of one eye finally had been absorbed, 10 eyes had persistent VH, 4 eyes of them had iris neouvasculrization, and 4 eyes of them had retinal detachment, and finally these 10 eyes underwent revitrectomy surgeries. The vision of the study group was better than that in the control group.
Conclusions
Intravitreal conbercept treatment can accelerate the clear-up of the VH, reduce the complication and the need of revitrectomy for PVDVH.
Key words:
Conbercept; Diabetic retinopathy; Recurrent vitreous haemorrhage